Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Core Insights - Neumora Therapeutics is advancing its clinical pipeline with multiple upcoming data readouts and has secured a $125 million venture debt facility to support its operations into 2027 [2][9][10] Pipeline Highlights - The company is on track to report topline data from NMRA-511 in Alzheimer's disease agitation by the end of 2025 [7] - Enrollment for KOASTAL-2 and KOASTAL-3 studies resumed in March 2025, with topline data expected in Q1 2026 and Q2 2026 respectively [5][6] - The M4 positive allosteric modulator (PAM) program is expected to enter clinical trials in mid-2025 [8] Financial Overview - As of March 31, 2025, Neumora had cash, cash equivalents, and marketable securities totaling $249.4 million [16] - Research and development expenses for Q1 2025 were $52.2 million, an increase from $45.8 million in Q1 2024 [16] - The company reported a net loss of $68.0 million for Q1 2025, compared to a net loss of $53.7 million for the same period in 2024 [16][18]